To receive all of the company’s financial communications in real time, please register directly by email at the following address: [email protected]
Presentation information:
Presentation title: Dual inhibition of post-radiogenic angio-vasculogenesis by olaptesed pegol (NOX-A12) and bevacizumab in glioblastoma – interim data from the first expansion arm of the German phase 1/2 GLORIA trial.
Presentation Type: Poster Presentation
Date: Friday, November 18, 2022
Time: 7:30 p.m. – 9:30 p.m. EST (1:30 a.m. – 3:30 a.m. CET, November 19, 2022)
Presenter: Dr. Frank Giordano, Chairman and Director of the Department of Radiology, University Hospital Bonn, Germany